Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

Participants who received concomitant medications which were ongoing at the start of treatment or started after the study treatment are included.

Time frame: Day 1 through 90 days after the last dose of study drug (approximately 45 months)

Population: As-treated population included all participants who received at least one dose of any study drug.

Participants with ECG abnormalities reported as TEAEs are reported.

Time frame: Day 1 through 90 days after the last dose of study drug (approximately 45 months)

Population: As-treated population included all participants who received at least one dose of any study drug.

Any laboratory abnormality during analysis of hematology, clinical chemistry, thyroid function tests, and urinalysis that was new in onset or worsened in severity or frequency from the baseline condition and required therapeutic intervention or diagnostic tests, led to discontinuation of study treatment, had accompanying or inducing symptoms or signs, or judged by the Investigator as clinically significant was recorded as AE. Participants with abnormal laboratory parameters reported as TEAEs are reported.

Time frame: Day 1 through 90 days after the last dose of study drug (approximately 45 months)

Population: As-treated population included all participants who received at least one dose of any study drug.

Vital sign assessment included body temperature, respiration rate, pulse oximetry, blood pressure, heart rate, and weight. Participants with abnormal vital sign and/or abnormal physical examination reported as TEAEs are reported.

Time frame: Day 1 through 90 days after the last dose of study drug (approximately 45 months)

Population: As-treated population included all participants who received at least one dose of any study drug.

Participants with shift \>=3 changed from baseline in ECOG status are reported. ECOG performance status is used by doctors and researchers to assess how a participant's disease is progressing, assess how the disease affects the daily living activities of the participant and determine appropriate treatment and prognosis. The scores are: 0 = Fully Active, able to carry out all pre-disease performance without restrictions; 1 = Restricted activity but ambulatory and able to carry out light work or work of a sedentary nature; 2 = Ambulatory and capable of self-care but unable to carry out work activities; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely Disabled, unable to carry out any self-care and totally confined to bed or chair; 5 = Dead.

Time frame: Day 1 through 90 days after the last dose of study drug (approximately 45 months)

Population: As-treated population included all participants who received at least one dose of any study drug.

An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. There will be no updated results for this outcome measures at the time of end of study.

Time frame: Day 1 through 90 days after the last dose of study drug (approximately 45 months)

Population: As-treated population included all participants who received at least one dose of any study drug.

The objective response is defined as confirmed complete response (CR) or confirmed partial response (PR) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) guidelines. The CR is defined as disappearance of all target and non-target lesions, no new lesions, and normalization of tumor marker level. The PR is defined as \>= 30% decrease in the sum of the diameters of target lesions compared to baseline and no new non-target lesion. A confirmed CR or PR is defined as 2 CRs or 2 PRs that were separated by at least 4 weeks with no evidence of progression or not evaluable response in-between. Percentage of participants with objective response is reported.

Time frame: Day 1 through end of study (approximately 45 months)

Population: Response-evaluable population included all participants with confirmed human papilloma virus Type 16 (HPV-16) or HPV-18 associated disease, who received one dose of both study drugs, had a baseline scan (Days -28 to -1) with measurable disease at baseline, and at least one follow-up scan with the opportunity to be followed for \>= 16 weeks.

The DCR is defined percentage of participants with CR, PR, or SD at 16 weeks based on RECIST v1.1 guidelines. A CR is defined as disappearance of all target and non-target lesions, no new lesions, and normalization of tumor marker level. A PR is defined as \>= 30% decrease in the sum of longest diameters of target lesions compared to baseline and no new non-target lesion. The SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum longest diameter since the study treatment started, and persistence of one or more non-target lesion(s) or / and maintenance of tumor marker level above the normal limits.

Time frame: Week 16

Population: As-treated population included all participants who received at least one dose of any study drug.

The DCR is defined percentage of participants with CR, PR, or stable disease (SD) at 16 weeks based on RECIST v1.1 guidelines. A CR is defined as disappearance of all target and non-target lesions, no new lesions, and normalization of tumor marker level. A PR is defined as \>= 30% decrease in the sum of longest diameters of target lesions compared to baseline and no new non-target lesion. The SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum longest diameter since the study treatment started, and persistence of one or more non-target lesion(s) or / and maintenance of tumor marker level above the normal limits.

Time frame: Week 16

Population: Response-evaluable population included all participants with confirmed HPV-16 or HPV-18 associated disease, who received one dose of both study drugs, had a baseline scan (Days -28 to -1) with measurable disease at baseline, and at least one follow-up scan with the opportunity to be followed for \>= 16 weeks.

Number of participants with positive ADA titer to durvalumab are reported. ADA prevalence is defined as ADA positive at any point (baseline and post-baseline); persistent positive is defined as ADA positive at Week 16, and transient positive is defined as positive at Week 8 but not at Week 16, regardless of baseline positivity.

Time frame: Pre-dose (up to 60 minutes prior to durvalumab administration) on Week 4, Week 8, and Week 16

Population: The ADA evaluable population included all participants who had non-missing baseline ADAs (on Day 1) and at least one non-missing post-baseline ADA result.

Overall survival is defined as the time from the date of start of study treatment until death due to any cause. Any participant not died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The OS was estimated using Kaplan-Meier method.

Time frame: Day 1 through end of study (approximately 45 months)

Population: As-treated population included all participants who received at least one dose of any study drug.

The objective response is defined as confirmed CR or confirmed PR based on irRECIST v1.1 guidelines. The irCR is defined as disappearance of all target and non-target lesions, no new lesions, and normalization of tumor marker level. The irPR is defined as \>= 50% decrease in the sum of the diameters of target lesions compared to baseline and no new non-target lesion. A confirmed irCR or irPR is defined as 2 irCRs or 2 irPRs that were separated by at least 4 weeks with no evidence of progression or not evaluable response in-between. Percentage of participants with objective response is reported.

Time frame: Day 1 through end of study (approximately 45 months)

Population: Response-evaluable population included all participants with confirmed HPV-16 or HPV-18 associated disease, who received one dose of both study drugs, had a baseline scan (Days -28 to -1) with measurable disease at baseline, and at least one follow-up scan with the opportunity to be followed for \>= 16 weeks.

The objective response is defined as confirmed CR or confirmed PR based on irRECIST v1.1 guidelines. The irCR is defined as disappearance of all target and non-target lesions, no new lesions, and normalization of tumor marker level. The irPR is defined as \>= 50% decrease in the sum of the diameters of target lesions compared to baseline and no new non-target lesion. A confirmed irCR or irPR is defined as 2 irCRs or 2 irPRs that were separated by at least 4 weeks with no evidence of progression or not evaluable response in-between. Percentage of participants with objective response is reported.

Time frame: Day 1 through end of study (approximately 45 months)

Population: As-treated population included all participants who received at least one dose of any study drug.

The objective response is defined as confirmed CR or confirmed PR based on RECIST v1.1 guidelines. The CR is defined as disappearance of all target and non-target lesions, no new lesions, and normalization of tumor marker level. The PR is defined as \>= 30% decrease in the sum of the diameters of target lesions compared to baseline and no new non-target lesion. A confirmed CR or PR is defined as 2 CRs or 2 PRs that were separated by at least 4 weeks with no evidence of progression or not evaluable response in-between. Percentage of participants with objective response is reported.

Time frame: Day 1 through end of study (approximately 45 months)

Population: As-treated population included all participants who received at least one dose of any study drug.

The PFS is defined as the time from the date of start of study treatment until the documentation of disease progression based on RECIST version 1.1 or death due to any cause, whichever occurs first. The progressive disease is defined at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started, the appearance of one or more new lesions, or unequivocal progression of existing non-target lesions. Participants who were not progressed or died at the time of the analysis were censored at the time of the latest date of assessment from their last evaluable RECIST version 1.1 assessment. The PFS was estimated using Kaplan-Meier method.

Time frame: Day 1 through end of study (approximately 45 months)

Population: As-treated population included all participants who received at least one dose of any study drug.

Serum concentrations of durvalumab is reported.

Time frame: Pre-dose (up to 60 minutes prior to durvalumab administration) on Week 4, Week 8, and Week 16

Population: Pharmacokinetics population included all participants who received at least one dose of durvalumab and had at least one evaluable post-dose serum concentration measurement of durvalumab. 'Number analyzed' denotes the number of participants evaluated for the specified time point.